Sean Mackay - 31 Aug 2024 Form 3 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
SVP & Chief Business Officer
Signature
/s/ Sean Mackay by Agnieszka Gallagher, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
31 Aug 2024
Net transactions value
$0
Form type
3
Filing time
03 Sep 2024, 17:49:08 UTC
Previous filing
21 Mar 2023
Next filing
24 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LAB Common Stock 392,168 31 Aug 2024 Direct F1
holding LAB Common Stock 207,832 31 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LAB Stock Option (Right to buy) 31 Aug 2024 Common Stock 600,000 $2.58 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock unites ("RSUs"). Each RSU represent the right to receive one share of common stock upon vesting. 1/4 of RSUs will vest on May 20, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F2 The shares underlying this option will vest as to 25% on May 20, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney